bizcommunity

RevnaBio revolutionises cancer diagnostics in West Afric with advanced molecular testing

Revna Biosciences (RevnaBio), a prominent precision medicine firm located in Ghana, is makir significant progress in its quest to meet unfulfilled requirements in cancer treatment.

Source: Derrick Akpalu, co-founder and chief executive officer of Revna Biosciences.

The company announced that data from its ongoing Ghana FDA-mandated cancer clinical research coveri solid and blood cancers has begun supporting product registration. This achievement comes a few month after RevnaBio successfully introduced advanced molecular tests in infectious diseases and maternal and child health.

RevnaBio's latest feat marks a significant step towards addressing West Africa's lack of advanced molecular diagnostic testing for cancer. The company's commitment to enhancing regional biomedical capabilities is evident in its technology localisation efforts.

In collaboration with precision medicine leader Diatech Pharmacogenetics, RevnaBio is addressing patier needs today for improved diagnostics and treatment options in future. The company's approach uses Diatech's EasyPGX & the Myriapod platforms, which provide qPCR IVD and NGS tests, the most comprehensive solutions for cancer precision medicine – a first in West Africa.

The chief executive officer of Diatech Pharmacogenetics, Oliva Alberti, said, "We are proud to collaborate with Revna Biosciences in this groundbreaking endeavour.

“Together, we're making personalised therapy more accessible in West Africa. Our role is to develop comprehensive assays for molecular profiling to aid in the fight against cancer. We're doing our part towar a future where every patient can access advanced molecular diagnostic testing."

Derrick Akpalu, co-founder and chief executive officer of Revna Biosciences, expressed optimism about t impact of their new developments.

He said, "We are pioneering today for a healthier tomorrow. At full deployment, the EasyPGX platform offe

up to 80% liquid biopsy capability, ensuring patients can have a blood draw for cancer testing here in Wes Africa. We are positive this will enhance our ongoing oncology research and clinical care efforts."

Akpalu also acknowledged the invaluable contributions of research participants and collaborating investigators from various teaching hospitals across Ghana.

He added, "Many thanks to our collaborating investigators at the Korle Bu Teaching Hospital, the 37 Militar Teaching Hospital, the Cape Coast Teaching Hospital and the Sweden Ghana Medical Centre for partneri with us. We look forward to activating many more study sites and sharing insights from this pivotal study as the study further matures."